# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates IGM Biosciences (NASDAQ:IGMS) with a Neutral and maintains $12 price...
Wedbush analyst Robert Driscoll reiterates IGM Biosciences (NASDAQ:IGMS) with a Outperform and maintains $20 price target.
IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(0.83) per share which met the analyst consensus estimate. This is ...